Aminoglycosides are antibacterial therapeutic agents that contain amino-modified glucose. They can kill bacteria like staphylococci and few mycobacteria. They also serve as a second line of defense against basic infections immune to basic antibacterials. Rising tuberculosis incidences in low-income countries will spur the demand for these agents.
For Market Research Report on “Aminoglycoside Market” Visit -http://www.grandviewresearch.com/industry-analysis/aminoglycoside-market
Health initiatives like UNITAID and Global Drug Facility (GDF) that manage alarming tuberculosis cases would influence the aminoglycoside market. Side effects (like muscle twitching and seizures) associated with this product can hinder the market.
The market was valued over USD 1.1 billion in 2014. It is projected to reach around USD 1.7 billion by 2022, at 3.5% CAGR during the forecast period (2015 to 2022). Disapproval of aminoglycoside medicines in certain regions should result in subordinate growth.
Streptomycin, kanamycin, neomycin, gentamicin, amikacin, and tobramycin are the products in the aminoglycoside market. Neomycin and tobramycin together constituted over USD 600 million. These drugs can treat major bacterial infections. Neomycin treats varied skin infections. Tobramycin is effective against Pseudomonas aeruginosa infections.
By administration routes, the market is divided into oral, feed, topical, intra-mammary, and injectables (parenteral). Among these, injectables accounted for the largest revenue. They treat tuberculosis, MDR-TB (multi-drug-resistant tuberculosis), and XDR-TB (extensively drug-resistant tuberculosis).
On the basis of applications, the aminoglycoside market is segmented into veterinary, skin infections, UTI (urinary tract infections) & pelvic diseases, and respiratory diseases. Respiratory diseases were the largest application in 2014. Veterinary treatment will experience limited growth over the forecast period on account of animal diseases.
In view of regions, Asia Pacific accounted for the largest share in 2014. This was attributed to alarming MDR-TB cases in the region. South Africa led the MEA (Middle East & Africa) market due to high regional demand for injectables. Unavailability of aminoglycosides in the United States will lead to decreased regional incomes.
Antibiotic resistance variations in different countries account for varied patterns, volumes, and revenues. Key players of the worldwide aminoglycoside market comprise Medson Pharmaceuticals, Vega Pharma Ltd., HuvePharma, and Kremoint Pharma Pvt. Ltd. Owing to shortage in the suppliers & manufacturers of some aminoglycoside medicines, new players are estimated to participate. However, absence of regulatory sanction could hinder their participation.
Information Source: Grand View Research